Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging
09636404 ยท 2017-05-02
Assignee
Inventors
- Bing Lou Wong (Irvine, CA, US)
- Norman Fung Man Wai (Vancouver, CA)
- Sui Yi Kwok (Hong Kong, CN)
- Man Kin Wong (Hong Kong, HK)
- Cornelia Wing Yin MAN (Hong Kong, HK)
Cpc classification
A61K45/06
HUMAN NECESSITIES
A61K51/088
HUMAN NECESSITIES
International classification
A61K51/00
HUMAN NECESSITIES
A61K51/08
HUMAN NECESSITIES
A61K45/06
HUMAN NECESSITIES
Abstract
The present invention provides a pharmaceutical composition containing hemoglobin-based therapeutic agent for treating cancer. The hemoglobin moiety can target cancer cells and the therapeutic moiety (i.e. active agent/therapeutic drug) can kill the cancer cells efficiently. The hemoglobin-based therapeutic agent used in the present invention can be used in the treatment of various cancers such as pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer, prostate cancer, stomach cancer and brain cancer. The composition can be used alone or in combination with other therapeutic agent(s) such as chemotherapeutic agent to give a synergistic effect on cancer treatment, inhibiting metastasis and/or reducing recurrence. The presently claimed hemoglobin-based 5FU-two-dye conjugate and/or hemoglobin-based 5FU-one-dye conjugate can also be used in live-cell imaging and diagnostic imaging.
Claims
1. A hemoglobin-based therapeutic agent for targeting cancer and treating the targeted cancer, said therapeutic agent comprising a chemically modified crosslinked hemoglobin molecule of, ##STR00001## wherein X is a crosslinked tetrameric hemoglobin.
2. A hemoglobin-based therapeutic agent for targeting cancer and treating the targeted cancer, said therapeutic agent comprising a chemically modified crosslinked hemoglobin molecule selecting from the group consisting of, ##STR00002## ##STR00003## ##STR00004## ##STR00005## ##STR00006## ##STR00007## ##STR00008## ##STR00009## wherein X is a crosslinked tetrameric hemoglobin.
3. A hemoglobin-based therapeutic agent for targeting cancer and treating the targeted cancer, said therapeutic agent comprising a chemically modified crosslinked hemoglobin molecule of, ##STR00010## wherein X is a crosslinked tetrameric hemoglobin.
4. A method of treating cancer comprising administering a composition comprising the therapeutic agent of claim 2 in a therapeutically effective amount, said composition is administered to a subject in needs thereof who suffers from said cancer.
5. The method of claim 4, wherein the therapeutically effective amount of said therapeutic agent is at 0.03 g of said therapeutic agent per kg of said subject.
6. The method of claim 4, wherein said composition further comprising a pharmaceutically acceptable carrier, salt, buffer, water, or a combination thereof.
7. The method of claim 4, wherein route of said administration comprises intravenous injection, intraperitoneal injection, and subcutaneous injections.
8. The method of claim 4, wherein said cancer comprises pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer and brain cancer.
9. The method of claim 4, wherein said cancer is tumor comprising hepatocellular carcinoma, liver cancer progenitor cells-induced tumor, glioblastoma, and triple negative progenitor cells-induced tumor.
10. A method of treating cancer comprising administering a composition comprising the therapeutic agent of claim 3 in a therapeutically effective amount, said composition is administered to a subject in needs thereof who suffers from said cancer.
11. The method of claim 10, wherein the therapeutically effective amount of said therapeutic agent is at 0.03 g of said therapeutic agent per kg of said subject.
12. The method of claim 10, wherein route of said administration comprises intravenous injection, intraperitoneal injection, and subcutaneous injections.
13. The method of claim 10, wherein said cancer comprises pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer and brain cancer.
14. The method of claim 10, wherein said cancer is tumor comprising hepatocellular carcinoma, liver cancer progenitor cells-induced tumor, glioblastoma, and triple negative progenitor cells-induced tumor.
15. A method of treating cancer comprising administering a composition comprising the therapeutic agent of claim 1 in a therapeutically effective amount, said composition is administered to a subject in needs thereof who suffers from said cancer.
16. The method of claim 15, wherein the therapeutically effective amount of said therapeutic agent is at 0.03 g of said therapeutic agent per kg of said subject.
17. The method of claim 15, wherein said composition further comprising a pharmaceutically acceptable carrier, salt, buffer, water, or a combination thereof.
18. The method of claim 15, wherein route of said administration comprises intravenous injection, intraperitoneal injection, and subcutaneous injections.
19. The method of claim 15, wherein said cancer comprises pancreatic cancer, leukemia, head and neck cancer, colorectal cancer, lung cancer, breast cancer, liver cancer, nasopharyngeal cancer, esophageal cancer and brain cancer.
20. The method of claim 15, wherein said cancer is tumor comprising hepatocellular carcinoma, liver cancer progenitor cells-induced tumor, glioblastoma, and triple negative progenitor cells-induced tumor.
Description
BRIEF DESCRIPTION OF THE DRAWINGS
(1)
(2)
(3)
(4)
(5)
(6)
(7)
(8)
(9)
(10)
(11)
(12)
(13)
(14)
(15)
(16)
(17)
(18)
(19)
(20)
(21)
(22)
(23)
(24)
(25)
(26)
(27)
(28)
(29)
(30)
(31)
(32)
(33)
DEFINITIONS
(34) The term cancer stem cell refers to the biologically distinct cell within the neoplastic clone that is capable of initiating and sustaining tumor growth in vivo (i.e. the cancer-initiating cell).
(35) The term cleavable conjugate refers to the conjugate with at least one cleavable linker and it can easily release the linked therapeutic drug/active agent by hydrolysis or redox reaction.
(36) The term non-cleavable conjugate refers to the conjugate with at least one non-cleavable linker and it cannot easily release the linked therapeutic drug/active agent by hydrolysis or redox reaction.
DETAILED DESCRIPTION OF INVENTION
(37) As discussed in the background, most cancerous tissues, such as cancerous tumors, are hypoxic. Hemoglobin can be used to alleviate the hypoxic condition. Hemoglobin plays an important role in most vertebrates for gaseous exchange between the vascular system and tissue. It is responsible for carrying oxygen from the respiratory system to the body cells via blood circulation and also carrying the metabolic waste product carbon dioxide away from body cells to the respiratory system, where the carbon dioxide is exhaled. Naturally-occurring hemoglobin is a tetramer which is generally stable when present within red blood cells. However, when naturally-occurring hemoglobin is removed from red blood cells, it becomes unstable in plasma and splits into two - dimers. Each of these dimers is approximately 32 kDa in molecular weight. These dimers may cause substantial renal injury when filtered through the kidneys and excreted. The breakdown of the tetramer linkage also negatively impacts the sustainability of the functional hemoglobin in circulation.
(38) In one embodiment of the present invention, the hemoglobin is stabilized by a cross-linker to form the stabilized tetramer. The stabilized hemoglobin has the oxygen transport feature and it can target cancerous cells or tissues in a human or animal body. The hemoglobin-based oxygen carrier is chemically modified and linked to the chemotherapeutic agent triggering a receptor-mediated mechanism and leading a combined chemotherapeutic agent to localize together in the cytoplasm of the cancerous cells in order to increase the efficacy of both hemoglobin-based oxygen carrier and the chemotherapeutic agent.
(39) A design for construction of a hemoglobin-based therapeutic drug is shown in
(40) Some therapeutic drugs (e.g. chemotherapeutic drug, 5FU) cannot be used in high dose because of high toxicity. In the present invention, the chemotherapeutic agent, 5FU, is chemically linked to the stabilized hemoglobin (65 kDa). The source of hemoglobin can be from, but not limited to, bovine, human, canine, porcine, equine and recombinant hemoglobin and/or subunits.
(41) The hemoglobin can be modified chemically by different functional groups before linking to the therapeutic drug. The hemoglobin can be modified by (1) anhydride, (2) ketene, (3) NHS ester, (4) isothiocyanates, (5) isocyanates, (6) activated esters (e.g. fluorophenyl esters, and carbonyl azides), (7) sulfonyl chlorides, (8) carbonyls followed by reductive amination, (9) epoxides, (10) carbonates, (11) fluorobenzenes, (12) imidoesters, (13) hydroxymethyl phosphine derivatives, (14) maleimides, (15) alkyl halides or haloacetamides, (16) disulfides, (17) thiosulfates, (18) aziridine-containing reagents, (19) acryloyl derivatives, (20) arylating agents, (21) vinylsulfone derivatives, (22) native chemical ligation (e.g. thioesters), (23) periodate oxidation of N-terminal serine or threonine to generate aldehydes for coupling with hydroxylamines, hydrazines, or hydrazides, (24) carbodiimides, (25) 4-sulfo-2,3,5,6-tetrafluorophenol, (26) carbonyl diimidazole, (27) sulfo-NHS, (28) diazoalkanes and diazoacetyl compounds, (29) Mannich condensation, (30) diazonium derivatives, (31) diazirine derivatives, (32) benzophenones and anthraquinones, (33) N-terminal modification by pyridoxal-5-phoshpate-based biomimetic transamination, (34) incorporation of bioorthogonal functionalities (e.g. alkynes and azides) with subsequent bioorthogonal conjugation reactions (e.g. dipolar addition Huisgen 1,3-dipolar additions of alkynes and azides, Staudinger ligation of azides and triarylphosphines, Diels-Alder reaction of alkenes and tetrazines, photochemical reaction of alkenes and tetrazoles), (35) metal carbenoids, (36) palladium-activated allyl reagents, (37) photoaffinity labeling agents.
(42) The modified hemoglobin linked with 5FU (Hb-FU) using non-cleavable linker (non-cleavable conjugate) is shown in
(43) The release of 5FU from (A) 5FU-carbinolamine (cleavable) model and 5FU-alkyl (non-cleavable) model and (B) hemoglobin-based 5FU with cleavable linker (Hb-5FU carbinolamine conjugate) is shown in
(44) Decomposition of 5FU-carbinolamine (cleavable) model is observed under the following conditions with the rate in descending order: 50% human plasma at 37 C.>PBS (pH 7.4) at 37 C.>PBS (pH 7.4) at room temperature (room temperature, 25 C.). The 5FU-alkyl (non-cleavable) model is stable under any of these conditions.
(45) Decomposition of hemoglobin-based 5FU with cleavable linker (Hb-5FU carbinolamine (cleavable) conjugate) is observed under the following conditions with the rate in the descending order: 50% human plasma at 37 C.>DB buffer (pH 7.4) at 37 C.
(46) The pharmaceutical composition of the present invention contains hemoglobin-based therapeutic agent targeting the cancer cells with therapeutic effect for cancer treatment. Our animal studies reveal suppression of tumor growth in hemoglobin based 5FU-treated mice in Pancreatic cancer xenograft (Capan-1) by 20-22% in tumor volume (
(47) The captioned hemoglobin based 5FU's ability in targeting other cancer cells are exemplified in various in vitro models. By employing the MTT assay, cytotoxicity of hemoglobin based 5FU on various cancer cells are determined: 20% cell death in HCT116 colorectal carcinoma (
(48) The structure of temozolomide (TMZ) and the modified hemoglobin linked with TMZ are shown in
(49)
(50) The condition for modification of hemoglobin by F-6-NHS is optimized for different parameters including pH, mole ratio and buffer.
(51) The condition for modification of hemoglobin by ketene is optimized for different parameters including pH, temperature and mole ratio.
(52) The condition for modification of hemoglobin by anhydride is also optimized for different parameters including pH and mole ratio.
(53) The structure of the modified hemoglobin linked with 5FU conjugate containing disulfide as cleavable linker (Hb-5FU-disulfide (cleavable) conjugate) is shown in
(54) For live-cell imaging or diagnostic imaging purpose, hemoglobin based 5FU conjugates are labeled with fluorescent dye e.g. fluorescein-6.
(55) For imaging purpose, hemoglobin based-5FU conjugates are also labeled with two fluorescent dyes (shown in
(56) No hemoglobin-based therapeutic agent is available in the market. The modified hemoglobin-based therapeutic agent containing pharmaceutical composition prepared in this invention can target to the cancer cells with therapeutic effect. For uses in cancer treatment, the modified hemoglobin-based therapeutic agent containing pharmaceutical composition of the present invention serves as an anti-cancer agent to kill cancer cells. The modified hemoglobin-based therapeutic agent is a good candidate to be used in low dose and can be combined with other molecular targeting or cytotoxic agents.
EXAMPLES
(57) The following examples are provided by way of describing specific embodiments of this invention without intending to limit the scope of this invention in any way.
Example 1a
(58) Synthesis of Ketene
(59) To a vigorously stirred solution of 5-hexyn-1-ol (4 mmol) and triethylamine (4.5 mmol) in dichloromethane (DCM) (100 mL), methylsulfonyl chloride (MsCl) (4.1 mmol in DCM) is added dropwise at 0 C. The mixture is then warmed to room temperature for stirring overnight. Sodium bicarbonate (aqueous) is poured into the reaction mixture and the organic phase is separated. The aqueous layer is extracted with DCM and the combined organic extracts are washed with water and brine, dried over magnesium sulfate (MgSO.sub.4) and the solvent evaporated. The crude mesylate is purified by flash column chromatography (20% ethyl acetate in n-hexane) to yield colorless oil.
(60) To a solution of mesylate (2 mmol) in acetone (60 mL), potassium iodide (2.5 mmol) is added in the reaction mixture and heated to reflux for 20 h. After cooling to room temperature, the precipitate is filtered off. The filter cake is washed with acetone (20 mL) and the solvent is evaporated. The residual oil is diluted with ether (100 mL) and washed with sodium thiosulfate solution (saturated, 10 mL). The aqueous solution is extracted with ether and the combined organic extracts are washed with brine, dried over anhydrous magnesium sulfate and the solvent is evaporated. The residue is fractionally distilled in vacuum to give the iodide compound 5-hexyn-1-iodide.
(61) Lithium bis(trimethylsilyl)amide (1 M in hexane, 20 mL) is added dropwise to a solution of phenylacetic acid methyl ester (2.73 g, 18.2 mmol) in dried tetrahydrofuran (40 mL) at 78 C. After 1 h, the reaction mixture is warmed to 0 C., and 5-hexyn-1-iodide (4.16 g, 20 mmol) in dried tetrahydrofuran (5 mL) is added dropwise to the solution. After stirring at 0 C. for 1.5 h, the reaction mixture is quenched with water washed, with a saturated ammonium chloride solution, and extracted with diethyl ether. The organic layers are combined and dried over anhydrous magnesium sulfate to give 4.17 g of alkyne-functionalized ester.
(62) A solution of alkyne-functionalized ester (4.17 g, 18.1 mmol) in methanol (100 mL) and water (2 mL) is treated with potassium hydroxide pellets (1.5 g, 27 mmol) and heated to reflux overnight. The reaction mixture was concentrated in vacuo. Water is added to the reaction mixture, which is subsequently washed with diethyl ether. The aqueous layer is collected and acidified with hydrochloric acid and then extracted with ether. The organic layers are combined, dried over anhydrous magnesium sulfate, and concentrated in vacuo to give alkyne-functionalized carboxylic acid as a colorless oil.
(63) To a solution of alkyne-functionalized carboxylic acid (1.08 g, 5 mmol) in dried dichloromethane (5 mL) at room temperature was added oxalyl chloride (2 M in dichloromethane, 5 mL) and the reaction mixture is stirred for 2 h. The solvent is distilled under nitrogen atmosphere to give a light yellow oil. The light yellow oil is dissolved in dried tetrahydrofuran (10 mL), and dried triethylamine (6 mL, 20 mmol) is added dropwise to the solution at 0 C. The resulting mixture is stirred at 0 C. for 2 h. The salt formed is filtered under nitrogen atmosphere, and the filtrate is distilled at 110 C. (1 mmHg) to give ketene as bright yellow oil.
Example 1b
(64) Modification of Peptide and Hemoglobin Using Ketene
(65) In a 1.0 mL eppendorf tube, peptide YTSSSKNVVR solution in water (1 mM, 10 L), ketene (10 equivalents, 1 L of a 100 mM stock solution of ketene in dried tetrahydrofuran), and phosphate buffer (pH 6.3 and 7.4, 80 L) are mixed. The reaction mixture is kept at room temperature for 2 h. The conversion of the peptide is determined from total ion count of LC-MS analysis of the reaction mixtures. Using MS/MS (tandem mass spectrometry) analysis, the N-terminal selectivity is determined.
(66) In a 1.0 mL eppendorf tube, the stabilized hemoglobin solution in buffer (1.56 mM, 40 L), ketene (10, 20, 30, 40, and 50 equivalents, 100 mM stock solution of ketene in dried tetrahydrofuran), and phosphate buffer (pH 6.3, 7.4 and 9, 160 L) are mixed. The reaction mixture is kept at room temperature overnight (one set at pH 9 at 37 C.). The conversions of the protein are determined from total ion count of LC-MS analysis of the reaction mixtures.
Example 2a
(67) Synthesis of Anhydride
(68) A solution of alkyne-functionalized carboxylic acid (100 mg, 0.46 mmol), (3-dimethyl aminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) (180.5 mg, 0.94 mmol), and triethylamine (0.5 mmol) in dichloromethane (20 mL) is stirred at room temperature overnight. The reaction mixture is washed with water. The organic layer is dried over anhydrous magnesium sulfate and concentrated in vacuo, and the residue is purified by flash column chromatography (eluting with 4% ethyl acetate in n-hexane) to give anhydride.
Example 2b
(69) Modification of Peptide and Hemoglobin Using Anhydride
(70) In a 1.0 mL eppendorf tube, peptide YTSSSKNVVR solution in water (1 mM, 10 L), anhydride (10 equivalents, 1 L of a 100 mM stock solution of anhydride in dried tetrahydrofuran), and phosphate buffer (pH 6.3 and 7.4, 80 L) are mixed. The reaction mixture is kept at room temperature for 2 h. The conversion of the peptide is determined from total ion count of LC-MS analysis of the reaction mixtures. Using MS/MS analysis, the N-terminal selectivity is determined.
(71) In a 1.0 mL eppendorf tube, stabilized hemoglobin solution in buffer (1.56 mM, 40 L), anhydride (10, 20, 30, 40, and 50 equivalents, 100 mM stock solution of anhydride in dried tetrahydrofuran), and phosphate buffer (pH 6.3, 7.4 and 9, 160 L) are mixed. The reaction mixture is kept at room temperature overnight (one set at pH 9 at 37 C.). The conversions of the protein are determined from total ion count of LC-MS analysis of the reaction mixtures.
Example 3a
(72) Synthesis of NHS Ester
(73) A solution of alkyne-functionalized carboxylic acid (100 mg, 0.46 mmol), N-hydroxysuccinimide (NHS) (64.4 mg, 0.56 mmol), (3-dimethyl aminopropyl)-3-ethylcarbodiimide hydrochloride (EDC) (180.5 mg, 0.94 mmol), and 4-di(methylamino)pyridine (DMAP) (0.5 mg, catalytic amount) in dichloromethane (20 mL) is stirred at room temperature overnight. The reaction mixture is washed with water. The organic layer is dried over anhydrous magnesium sulfate and concentrated in vacuo, and the residue is purified by flash column chromatography (eluting with 50% ethyl acetate in n-hexane) to give NHS ester.
Example 3b
(74) Modification of Peptide and Stabilized Hemoglobin Using NHS Ester
(75) A 6.8 L (10 nmol) of stabilized hemoglobin solution (100 mg/mL, 1.56 mM) or 10 L of YTSSSKNVVR stock solution (1 mM) is added into a mixed solution of 180 L PBS (pH 7.4, 10 mM) buffer with 5 L dimethylsulfoxide (DMSO) in a 1.5 mL eppendorf tube (stabilized hemoglobin/YTSSSKNVVR final concentration: 0.05 mM). Fresh NHS ester (0.8 mg) solution (2 mM) in dry tetrahydrofuran (1 mL) is added in portions of 0.5 L (0.1 equivalents/portion, 10, 20 and 40 portions) and 1.0 L (0.2 equivalents/portion, 5, 10 and 20 portions) per addition per 2 min and immediately followed by vortex. The addition is finished within 90 min and the reaction solution is allowed to keep at room temperature for another 2.5 h. Subsequently, 10 L of ethanolamine solution (20 mM) in PBS (pH 7.4, 10 mM) buffer is added to the reaction solution to quench the remaining free NHS ester at room temperature for 3 h.
Example 4a
(76) Modification of the Stabilized Hemoglobin with Fluorescein 6-NHS Ester
(77) The stabilized hemoglobin solution (9.9 g/dL) is modified by fluorescein 6-carboxysuccinimidyl ester (F-6-NHS). The reaction conditions (pH, ratio, time, buffer) are optimized and the reaction mixture is characterized by LC-ESI MS. The stabilized hemoglobin solution is adjusted to different pH (pH 8.0, 8.3, 8.5, 8.8 and 9.0 respectively) by acetic acid (0.2 M) and sodium hydroxide (0.1 M) under nitrogen. Different equivalents (3, 5, 7, and 9 equiv. respectively) of F-6-NHS in DMSO is added dropwise to the stabilized hemoglobin solution and stirred for different reaction times (2, 3, 4, and 5 h respectively) under nitrogen in the dark. The excess F-6-NHS is removed by Bio Spin Tris 30 column (10 k) (or ultra amicon 4 mL: 3 k). The modified hemoglobin solution is stored in RA buffer (pH 7.5) and characterized by LC-ESI MS.
Example 4b
(78) Conversion for F-6-NHS-Modified Hemoglobin Under Different pH
(79) The conversion of each unit of F-6-NHS-modified hemoglobin under different pH (pH 8.0, 8.3, 8.5, 8.8, and 9.0) is optimized. The conversion is determined from total ion count of LC-MS analysis of the reaction mixtures. The modification is performed in the ratio of 3:1 for F-6-NHS to stabilized hemoglobin in 1 mL RA buffer for 4 h in the dark. The result is shown in
Example 4c
(80) Conversion for F-6-NHS-Modified Hemoglobin at Different Ratios of F-6-NHS to Stabilized Hemoglobin
(81) The conversion of each unit of F-6-NHS-modified hemoglobin with different ratios of F-6-NHS to stabilized hemoglobin (3, 5, 7, and 9 equivalents) in 1 mL RA buffer at pH 8.5 for 4 h in the dark. The stabilized hemoglobin concentration is 9.9 g/dL. The conversion is determined from total ion count of LC-MS analysis of the reaction mixtures. The result is shown in
Example 4d
(82) Conversion for F-6-NHS-Modified Hemoglobin at Different Reaction Times
(83) The conversion of each unit of F-6-NHS-modified hemoglobin with 7 equivalents of F-6-NHS to stabilized hemoglobin in 1 mL RA buffer of pH 8.5 for different reaction times (2, 3, 4, and 5 h) in the dark. The stabilized hemoglobin concentration is 9.9 g/dL. The conversion is determined from total ion count of LC-MS analysis of the reaction mixtures. The preferred reaction time is at 4 h.
Example 4e
(84) Conversion for F-6-NHS-Modified Hemoglobin in Different Buffers
(85) The conversion of each unit of F-6-NHS-modified hemoglobin with 7 equivalents of F-6-NHS to stabilized hemoglobin in different buffers (acetate, carbonate, and phosphate buffer) at pH 8.5 for 4 h in the dark. The stabilized hemoglobin concentration is 9.9 g/dL. The conversion is obtained from the ratio of the mass intensity of modified-unit with the sum of the mass intensity of the corresponding unit. The result is shown in
Example 5a
(86) Synthesis of 5FU-Carbinolamine(Cleavable) NHS Ester
(87) A solution of 5FU carbinolamine succinic acid (375 mg, 1.86 mmol), N-hydroxysuccinimide (299 mg, 2.60 mmol), N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC, 499 mg, 2.60 mmol) and 4-dimethylaminopyridine (DMAP, 30 mg, catalyst.) in dichloromethane (20 mL) and dimethylformamide (DMF) (1 mL) is stirred at room temperature under N.sub.2 atmosphere for 18 h. The precipitate is filtered to give the 5FU-carbinolamine (cleavable) NHS ester.
Example 5b
(88) Modification of Hemoglobin with 5FU-Carbinolamine(Cleavable) NHS Ester
(89) A 1 mL of modified hemoglobin solution (10 g/dL, 1.56 mM, DB buffer, pH 8.5) is added with 110 L of 5FU-carbinolamine(cleavable) NHS ester (100 mM, 7 equivalents) in DMSO. The reaction solution is stirred at room temperature for 4 h, followed by purification using bio-gel P-30 gel and characterization by ESI-MS. The estimated conversion yield is 95%. About 6 molecules of 5-FU cleavable are conjugated onto one molecule of modified hemoglobin.
Example 6a
(90) Synthesis of 5FU Non-Cleavable NHS Ester
(91) To a solution of 5FU (1.00 g, 7.69 mmol) in DMF (6 mL), is added triethylamine(1.08 mL, 7.69 mmol) dropwise. After stirring for 10 minutes, methyl acrylate (1.38 mL, 15.4 mmol) is added dropwise. The reaction mixture is kept stirring at room temperature for 20 h. The crude mixture is concentrated in vacuo and purified by flash chromatography with silica gel (eluting with 5% MeOH/DCM) to give methyl ester as product. To a solution of methyl ester (650 mg, 3.00 mmol) is dissolved in 5% HCl (35 mL). The reaction mixture is heated under reflux for 3 h. When the reaction mixture is cooled, H.sub.2O (20 mL) is added and the organic layers are extracted with ethyl acetate (620 mL). The combined organic layers are then dried (MgSO.sub.4), filtered and concentrated in vacuo. The residue is purified by flash chromatography (eluting with 10% MeOH/DCM).
(92) A solution of the obtained product (375 mg, 1.86 mmol), N-hydroxysuccinimide (299 mg, 2.60 mmol), N-(3-Dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC, 499 mg, 2.60 mmol) and 4-dimethyl aminopyridine (DMAP, 30 mg, catalyst) in DCM (20 mL) and DMF (1 mL) is stirred at room temperature under N.sub.2 atmosphere for 18 h. The precipitate is filtered to give 5FU-alkyl (non-cleavable) NHS ester.
Example 6b
(93) Modification of Hemoglobin with 5FU Non-Cleavable NHS Ester
(94) A 1 mL of modified hemoglobin solution (10 g/dL, 1.56 mM, DB buffer, pH 8.5) is added with 110 L of 5FU non-cleavable NHS (100 mM, 7 equivalents) in DMSO (dimethyl sulfoxide). The reaction solution is stirred at room temperature for 4 h, followed by purification using bio-gel P-30 gel and characterization by ESI-MS. The estimated conversion yield is 95%. About 6 molecules of 5FU non-cleavable are conjugated onto one molecule of modified hemoglobin.
Example 7a
(95) Synthesis of Cleavable 5FU Disulfide N-Hydroxysuccinimide Ester
(96) To a solution of 5FU-1-propionic acid N-hydroxysuccinimide ester (179 mg, 0.6 mmol), 4-[[2-[(2-aminoethyl)dithio]ethyl]amino]-4-oxo-butanoic acid (126 mg, 0.5 mmol) in DMF (5 mL), is added triethylamine(0.25 mL, 0.75 mmol) dropwise. The reaction mixture is kept stirring at room temperature (25 C.) for 4 h. The crude mixture is concentrated in vacuo and purified by flash chromatography (eluting with 5% CH.sub.3OH/CH.sub.2Cl.sub.2) to give product 5FU-disulfide (cleavable) succinic acid.
(97) A solution of 5FU disulfide succinic acid (109 mg, 0.25 mmol), N-hydroxysuccinimide (58 mg, 0.5 mmol), N-(3-Dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC, 96 mg, 0.5 mmol) and 4-dimethylaminopyridine (DMAP, 1 mg, cat.) in DMF (5 mL) is stirred at room temperature (25 C.) under N.sub.2 atmosphere for 12 h. The crude reaction mixture is concentrated in vacuo. The residue is purified by flash chromatography (eluting with 5% CH.sub.3OH/CH.sub.2Cl.sub.2) to give product 5FU-disulfide (cleavable) NHS ester as a white solid.
Example 7b
(98) Modification of Hemoglobin with 5FU-Disulfide (Cleavable)-NHS
(99) A 1 mL of modified hemoglobin solution (10 g/dL, 1.56 mM, DB buffer, pH 8.5) is added with 110 L of 5FU-disulfide (cleavable) NHS ester (100 mM, 7 equivalents) in DMSO. The reaction solution is stirred at room temperature for 4 h, followed by purification using bio-gel P-30 gel and characterization by ESI-MS. About 4 molecules of 5FU disulfide are conjugated onto one molecule of modified hemoglobin.
Example 8
(100) Synthesis of Temozolomide Disulfide N-Hydroxysuccinimide Ester
(101) To a stirred solution of temozolomide acid N-hydroxysuccinimide ester (146 mg, 0.5 mmol) and 4-[[2-[(2-aminoethyl)dithio]ethyl]amino]-4-oxo-butanoic acid (126 mg, 0.5 mmol) in dry DMF (5 mL) in an ice water bath is added dropwise triethylamine (0.3 mL, 0.55 mmol). The mixture is warmed up to room temperature (25 C.) and then stirred for 4 h. The crude reaction mixture is concentrated in vacuo. The residue is purified by flash chromatography (eluting with 40% CH.sub.3OH/CH.sub.2Cl.sub.2) to give product temozolomide disulfide succinic acid as white solid.
(102) A solution of temozolomide disulfide succinic acid (78.5 mg, 0.18 mmol), N-hydroxysuccinimide (31 mg, 0.27 mmol) and N-(3-Dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC, 52 mg, 0.27 mmol) in DMF (1 mL) is stirred at room temperature (25 C.) under N.sub.2 atmosphere for 12 h. The crude reaction mixture is concentrated in vacuo. The residue is purified by flash chromatography (eluting with 5% CH.sub.3OH/CH.sub.2Cl.sub.2) to give product temozolomide disulfide N-hydroxysuccinimide ester as white solid.
Example 9
(103) Modification of Hemoglobin with Fluorescein 6-NHS and 5FU Cleavable NHS Ester
(104) A 1 mL of modified hemoglobin solution (10 g/dL, 1.56 mM, DB buffer, pH 8.5) is added with 55 L of fluorescein 6-NHS (100 mM, 3.5 equivalents) in DMSO and 55 L of 5FU cleavable NHS (100 mM, 3.5 equivalents) in DMSO. The reaction solution is stirred at room temperature for 4 h, followed by purification using bio-gel P-30 gel and characterization by ESI-MS. About 2.5 molecules of 5FU cleavable and 2.5 molecules of fluorescein are conjugated onto one molecule of modified hemoglobin.
Example 10
(105) Modification of Hemoglobin with Fluorescein 6-NHS and 5FU Non-cleavable NHS Ester (Labeled with One Fluorescent Dye)
(106) A 1 mL of modified hemoglobin solution (10 g/dL, 1.56 mM, DB buffer, pH 8.5) is added with 55 L of fluorescein 6-NHS (100 mM, 3.5 equivalents) in DMSO and 55 L of 5FU non-cleavable NHS (100 mM, 3.5 equivalents) in DMSO. The reaction solution is stirred at room temperature for 4 h, followed by purification using bio-gel P-30 gel and characterization by ESI-MS. About 2.5 molecules of 5FU non-cleavable and 2.5 molecules of fluorescein are conjugated onto one molecule of modified hemoglobin.
Example 11
(107) Synthesis of Different Compounds for Hemoglobin-5FU-Two-dye Conjugate (Labeled with Two Fluorescent Dyes) for Live-Cell Imaging
(108) For synthesis of hemoglobin-5FU-Two-dye Conjugate for Live-Cell Imaging, precursors include copper lysine complex, 5FU lysine, 5FU dansyl lysine, 5FU dansyl lysine NHS ester, 5FU dansyl lysine ethanolamine, 5FU dansyl lysine succinic acid, 5FU dansyl lysine NHS ester.
Example 11a Formation of Copper Lysine Complex
(109) To a solution of L-lysine (3.14 g, 17.2 mmol) in sodium hydrogencarbonate solution (1 M, 40 mL), is added copper (II) sulphate (pentahydrate, 2.15 g, 8.60 mmol) in single portion. The dark blue suspension is stirred for 3 h prior to addition of methanol (15 mL). The reaction is left stirring for 24 h at room temperature. The resulting blue slurry is filtered and dried in vacuo to give copper-lysine complex (blue powder).
Example 11b Formation of 5FU Lysine
(110) Copper lysine complex (72.4 mg, 0.21 mmol) and sodium bicarbonate (34.4 mg, 0.41 mmol) are dissolved in H.sub.2O (5 mL). After 1 h of stirring at room temperature, 5FU-alkyl (non-cleavable) NHS ester (123 mg, 0.41 mmol) is added to the cloudy blue suspension. Stirring continued at room temperature for 16 h, during which time a colour change to a clear light blue (with no precipitation) is observed. Sodium sulfide (16.4 mg, 0.21 mmol) is then added and the reaction mixture turned greyish-brown. The crude mixture is neutralized to pH 4 using dilute hydrochloric acid. The precipitate is then filtered and the remaining filtrate is concentrated in vacuo and washed with cold methanol (20 mL). The crude clear residue is obtained and is used in the next step without purification.
Example 11c Formation of 5FU Dansyl Lysine
(111) To a solution of 5FU lysine (271 mg, 0.82 mmol) in dimethylformamide (6 mL) at 0 C. is added triethylamine (2 mL) dropwise. After stirring for 15 min, 5-(dimethylamino)naphthalene-1-sulfonyl chloride (270 mg, 1.00 mmol) is added and a colour change from clear to greenish-brown is observed upon the addition. After stirring in the dark at room temperature for 24 h, the reaction mixture is concentrated in vacuo prior to purification by flash chromatography (eluting with 20% methanol/dichloromethane) to yield 5FU dansyl lysine as yellow solid.
Example 11d Formation of 5FU Dansyl Lysine NHS Ester
(112) To a solution of 5FU dansyl lysine (98.0 mg, 0.17 mmol) in dimethylformamide (3 mL), is added N-hydroxysuccinimide (50.4 mg, 0.26 mmol), N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (30.0 mg, 0.26 mmol) and 4-(dimethylamino)pyridine (4 mg, catalyst). The reaction mixture is stirred in the dark at room temperature for 18 h. After that, the reaction mixture is concentrated in vacuo prior to purification by flash chromatography (eluting with 20% methanol/dichloromethane) to yield 5FU dansyl lysine NHS ester as a yellow solid.
Example 11e Formation of 5FU Dansyl Lysine Ethanolamine
(113) To a solution of 5FU dansyl lysine NHS ester (103 mg, 0.16 mmol) in dimethylformamide (1.5 mL) at room temperature, is added ethanolamine (500 L) dropwise. The reaction mixture is stirred in the dark for 12 h. After that, the reaction mixture is concentrated in vacuo prior to purification by flash chromatography (eluting with 20% methanol/dichloromethane) to yield 5FU dansyl lysine ethanolamine as a yellow solid.
Example 11f Formation of 5FU Dansyl Lysine Succinic Acid
(114) To a solution of 5FU dansyl lysine ethanolamine (28.0 mg, 0.05 mmol) in tetrahydrofuran (2 mL), is added triethylamine (0.50 mL) and succinic anhydride (40.0 mg, 0.42 mmol). The reaction mixture is heated to reflux for 3 h. Once cooled, the reaction mixture is concentrated in vacuo and is purified by flash chromatography (eluting with 20% methanol/dichloromethane) to yield 5FU dansyl lysine succinic acid as a yellow solid.
Example 11g Formation of 5FU Dansyl Lysine NHS Ester
(115) To a solution of 5FU dansyl lysine succinic acid (26.0 mg, 0.04 mmol) in dimethylformamide (1 mL), is added N-hydroxysuccinimide (18.0 mg, 0.07 mmol), N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (22.0 mg, 0.07 mmol) and 4-(dimethylamino)pyridine (2 mg, catalyst). The reaction mixture is stirred in the dark at room temperature for 20 h. The solvent is removed in vacuo and the crude residue is purified by flash chromatography (eluting with 20% methanol/dichloromethane) to yield 5FU dansyl lysine NHS ester as a yellow film.
Example 12
(116) Modification of Hemoglobin with TAMRA-NHS and 5FU-Dansyl NHS Ester for Live Cell Imaging
(117) A 1 mL of modified hemoglobin solution (10 g/dL, 1.56 mM, DB buffer, pH 8.5) is added with 55 L of TAMRA NHS (100 mM, 3.5 equivalents) in DMSO and 55 L of 5FU-Dansyl NHS (100 mM, 3.5 equivalents) in DMSO. The reaction solution is stirred at room temperature for 4 h, followed by purification using bio-gel P-30 gel and characterization by ESI-MS. About 2 molecules of 5FU-Dans and 2 molecules of TAMRA are conjugated onto one molecule of modified hemoglobin.
Example 13
(118) Culture and Reagents for Different Cancer Cell Lines
(119) Cancer cells are cultured in DMEM (Invitrogen) with 10% Fetal bovine serum (FBS), 100 U/mL penicillin and 100 g/mL streptomycin at 37 C. For normoxic condition, cells are incubated with ambient O.sub.2 concentration and 5% CO.sub.2; for hypoxic condition, cells are incubated with 0.1-0.5% O.sub.2 (Quorum FC-7 automatic CO.sub.2/O.sub.2/N.sub.2 gas mixer) and 5% CO.sub.2. Culture conditions for both adherent and non-adherent cancer cell lines used are comparable, including liver cancer cells HepG2, Huh7 and SMMC7221, breast cancer cells 4T1, MCF7 and MDA-MB231, Glioblastoma brain cancer cells A172 and U87MG, Colorectal carcinoma cells HCT116 and HT29, leukemic cells H60 and Jurkat, Non-Small cell Lung cancer cells A549 and H460, Pancreatic cancer cells JF305 and Capan-1.
Example 14
(120) Isolation, Culture and Reagents for Cancer Stem-Like/Progenitor Cells
(121) Putative liver and breast cancer stem-like cells/progenitor cells (CD133+LCSCs and CD44+/CD24 BCSCs) are sorted or isolated from human liver cancer cells using Flow Cytometric Analysis. These sorted cells have the potential to self-renew and differentiate, to be able to form tumours in NOD/SCID mice when injected with only a small numbers, to be able to form spheroids in vitro, and are highly chemoresistant in nature. Fluorescence Activated Cell Sorting (FACS) is performed on HepG2 liver cancer cells using PE-conjugated monoclonal mouse anti-human CD133 (BD Biosciences); and on MCF7 breast cancer cells using PE-conjugated monoclonal mouse anti-human CD24 and APC-conjugated monoclonal mouse anti-human CD44 (BD Biosciences). Isotypes IgG1k-PE, IgG2B-PE and IgG2Akappa-APC (Coulter Ltd.) serve as controls. Samples are analyzed and sorted on a FACS Aria II (BD Biosciences). The 25% most brightly stained or the bottom 25% most dimly stained cells are selected as positive and negative populations. Stemness of the sorted cells is verified by subsequent Western Blotting and staining of CD133, Oct 4 and Sox2 pluripotency markers.
(122) The sorted LCSCs are subsequently transferred to non-adherent culture condition in human Mammocult basal medium (Stem Cell Technology Ltd.) supplemented with human Mammocult proliferation supplement (Stem Cell Technology Ltd.), 0.48 g/mL freshly dissolved Hydrocortisone, and 4 g/mL Heparin fresh before use. No antibiotics are added to the medium. The freshly prepared medium is filtered using 0.2 m low-protein binding filters (Millipore Ltd). The LCSC spheroids are allowed to grow in suspension until they reach the size of about 70 m in diameter. LCSC spheroids exceed the sizes of 70 m are sub-cultured by centrifugation at 1000 rpm for 3 min, followed by physical dissociation with trypsin-EDTA for 1 min and subsequent re-suspension in new medium.
Example 15
Live Cell Time-lapse Microscopy in Cancer Cells
(123) Cancer cells (e.g. HepG2 liver cancer cells) are seeded onto glass bottom microwell dishes (MatTek Corporation). Live cells at defined zooms (63, 20) are acquired using Zeiss Observer Z1 widefield microscope, equipped with atmospheric/temperature-controlled chamber and motorized stage for multi-positional acquisition. The incubation is performed in an enclosed live cell imaging system purged with 0.1% O2 and 5% CO2 (premixed). Cells are exposed to (1) Hb-5FU-alkyl(non-cleavable)-FL conjugate, labeled with one fluorescent dye and (2) Hb-5Fu-Dan-TAM conjugate, labeled with two fluorescent dyes; for 15 min prior to the acquisition of images every 3 min for a period of 2 h. Images are deconvolved and compacted into time-lapse movies using the MetaMorph software (Molecular Device). The images are shown in
Example 16
(124) Cytotoxicity Assay on Cancer Cell Lines
(125) Cell viability is measured using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) proliferation assay. Briefly, cancer cell lines (e.g. HepG2 or Huh7 liver cancer cells) are seeded in a 96-well flat-bottomed microplate (6000 cells/well) and cultured in 100 L, growth medium at 37 C. and 5% CO.sub.2 for 24 h. Cell culture medium in each well is then replaced by 100 L, cell growth medium, containing either no drug, 5FU alone or modified hemoglobin-based 5FU (Hb-FU) with another chemotherapeutics at their IC.sub.50 concentrations. Incubation of 5FU or Hb-FU for 24 h, 20 L, MTT labeling reagent (5 mg/mL in PBS solution) is added to each well for further 4 h at 37 C. The growth medium is removed gently, and 200 L, DMSO is then added to each well as solubilizing agent to dissolve the formazan crystals completely. The absorbance at the wavelength of 570 nm is measured by Multiskan EX (Thermo Electron Corporation), and each data point represents the meansSD from triplicate wells.
Example 17
(126) Establishment of Various Tumor Xenograft Models in Immunodeficient Nude & NOD/SCID Mice and Dosing Regimen
(127) Human cancer cells are inoculated into balb/c nude mice to establish two subcutaneous tumor models Animals are randomized and assigned into 9 different groups (4-8 mice per group) prior to treatments. Animals received either: (1) RA-buffer, (2) stabilized hemoglobin alone (4 doses, 1 dose per week) at 0.4 g/kg (for human: 0.03 g/kg) (intravenous injection, i.v.), (3) 5FU (4 doses, 1 dose per week) at 80 mg/kg (i.v.), (4) co-administration of 5FU and stabilized hemoglobin (stabilized hemoglobin given 1 h prior to 5FU treatment), (5) multiple doses of stabilized hemoglobin (stabilized hemoglobin given on day 1 and on day 4, for 4 weeks), (6) Non-cleavable form of stabilized hemoglobin conjugated with 5FU (4 doses, 1 dose per week) at 0.4 g/kg (i.v.), and (7) Cleavable form of stabilized hemoglobin conjugated with 5FU (4 doses, 1 dose per week) at 0.4 g/kg (i.v.).
(128) Tumorigenicity of the cancer cells is determined by subcutaneous injection of 1-510.sup.6 of cancer cells into the flank of 5-week old balb/c nude mice. For cancer progenitor cells, 110.sup.5 of successfully isolated progenitor cells are subcutaneously injected into the NOD/SCID mice for xenograft establishment. Each group contains four to eight animals. After tumors are detected at around 0.3-0.5 cm3, tumor size is measured every 3 days by calipers, and tumor volumes are calculated as volume (cm3)=(LWW)/2. Mice are weight on the day of sacrifice and harvested tumors are weighted and imaged immediately after sacrifice.